Linvoseltamab vs standard treatment for relapsed myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+).
- Your daily ability is good enough (ECOG 0–1; ECOG 2 may be allowed if it’s only from myeloma-related symptoms like pain).
- You’ve had 1 to 4 prior myeloma treatment “lines,” and your disease has progressed after the last one (with extra prior-treatment rules depending on where you live).
- Your cancer can be measured on tests, so doctors can track response.
- Your blood counts, liver, kidneys, heart, and blood calcium are adequate around screening, and you expect to live at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (linvoseltamab and tocilizumab) for adults with multiple myeloma that has stopped responding to standard treatments. Tocilizumab is added to help reduce serious side effects from the main drug.
This trial tests whether REGN17372 plus linvoseltamab is safe for people with multiple myeloma that has come back or not responded to prior treatments. You may join if you have tried at least 3 other therapies.
This trial tests a combination of two drugs—elranatamab and isatuximab—for people with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see if this new combination can help control the disease.
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
This trial tests a new drug called linvoseltamab for people with AL amyloidosis that has returned or is not responding to treatment. It aims to see if the drug is safe and helps control the disease.
Hear when a new Relapsed Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.